LX211

Phase 3Small molecule

LLux Biosciences, Inc.

LX211 is one of 51 small molecule programs targeting Non-Infectious Anterior Uveitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Infectious Anterior UveitisActive, not recruiting

UveitisActive, not recruiting

Non-Infectious Anterior UveitisPhase 3

Active, not recruiting

UveitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

94 competitors in Uveitis

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 3

3 2

Pred Forte

Novartis

Phase 3

2 3

Olumiant

Eli Lilly

Phase 3

1 4

Roferon-a

Roche

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 3

5 6

Cosentyx

AIN457

6 8

Zinbryta

Roche

Phase 2

5 9

Avastin

Actemra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uveitis3 trials

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

Completed·LLux Biosciences, Inc.·Phase 3·NCT00404612·218 enrolled

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

Completed·LLux Biosciences, Inc.·Phase 3·NCT00404742·232 enrolled

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

Completed·LLux Biosciences, Inc.·Phase 3·NCT01243983·155 enrolled

Non-Infectious Anterior Uveitis1 trial

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Completed·LLux Biosciences, Inc.·Phase 3·NCT00404885·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for LX211. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LX211 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LX211. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lux Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLux Biosciences, Inc.

LX211

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Uveitis3 trials

Non-Infectious Anterior Uveitis1 trial

References

Drug Info

Quick Facts

Related News